阿德福韦酯联合胸腺肽a1治疗HBeAg阳性慢性乙型肝炎的近期疗效观察

目的观察阿德福韦酯联合胸腺肽a1治疗HBeAg阳性慢性乙型肝炎临床疗效及对HBeAg、HBV-DNA的影响。方法128例HBeAg阳性慢性乙型肝炎随机分为两组，治疗组68例，对照组60例；治疗组为阿德福韦酯胶囊和胸腺肽a1；对照组为单用阿德福韦酯，疗程48wk。肝肾功能、血常规检测4wk一次；HBV-DNA、乙肝五项血清学指标12wk检测一次；每组均有25例于治疗前及治疗48wk后进行肝脏组织学检查。结果两组HBeAg转换、ALT复常率比较无统计学意义（P〉0．05），治疗组HBV-DNA转阴率高于对照组（P〈0．05）；肝组织病理：炎症活动度，纤维化程度两组比较有统计学意义（P〈0．01）。结论阿德福韦酯联合胸腺肽a1治疗HBeAg阳性慢性乙型肝炎在一定程度上能提高疗效，远期疗效有待进一步研究。

The therapeutic efficiency observation of adefovir joint thymosin alpha 1 in the treatment of HBeAg positive chronic hepatitis B

Objective To observe clinical curative effect ofadefovir joint thymosin alpha 1 in the treatment of HBeAg positive chronic hepatitis B and the influence on HBV-DNA. Methods 128 cases of chronic hepatitis b with positive HBeAg were randomly divided into two groups： treatment group 68 cases, control group 60 patients. The treatment group received therapy for adefovir capsule and thymosin alpha 1, Control for single adefovir treatment 48 weeks. Liver function, blood routine were detected every 4 weeks; HBV-DNA, hepatitis B five serological index were detected every 12 weeks; Each group has 25 cases that received histological examination before treatment and 48 weeks after the treatment. Results HBeAg conversion rate, ALT normaization rate is not statistically significant （P〉0.05）; the conversion rate of HBV-DNA in the treatment group is significantly higher than in the control group （P〈0.05）; Liver tissue pathology, inflammation, and fibrosis degree between two groups was statistically significant （P〈0.01）. Conclusions Adefovir joint thymosin alpha 1 could elevate the therapeutic efficiency of HBeAg positive chronic hepatitis B in a certain degree, prostecdtive efficacy need further long term follow-up research.